XAIR Earnings Prediction
The chart below shows how XAIR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, XAIR sees a -2.02% change in stock price 10 days leading up to the earnings, and a -19.01% change 10 days following the report. On the earnings day itself, the stock moves by +1.57%. This data can give you a slight idea of what to expect for the next quarter's release.
XAIR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
798.00K
233.89%
16.84%
Gross Margin
-135.84%
68.22%
178.59%
Operating Margin
-1608.15%
-78.08%
-19.12%
Net Margin
-1758.02%
-75.89%
-8.03%
EPS
-0.28
-45.10%
3.70%
No Data Available
XAIR Earnings Analysis
Beyond Air, Inc. Common Stock Corporation (XAIR.O) Earnings Conference Call
Positive
Client Growth Surge: During the quarter ended September 30, 2024, we increased our total number of hospital clients by over 60%.
Quarterly Revenue Comparison: Revenue for the second fiscal quarter of 2025 was $0.8 million compared with $0.2 million in our fiscal second quarter of 2024.
Positive Gross Margins Expected: We expect gross margins to turn positive in the March 2025 quarter.
R&D Expense Decrease: Research and development expenses for the three months ended September 30, 2024 were $4.6 million compared to $7.1 million for the three months ended September 30, 2023, reflecting a decrease of $2.5 million.
Cash and Marketable Securities: As of September 30, 2024, the company had cash, cash equivalents and marketable securities of $28.4 million.
Negative
Quarterly Revenue Comparison: Revenue for the second fiscal quarter of 2025 was $0.8 million compared with $0.2 million in our fiscal second quarter of 2024.
Gross Margin Loss Comparison: We're showing a $1.1 million loss in gross margin for the fiscal second quarter of 2025 compared to a $0.2 million loss for the same period last year.
Cost Exceeds Revenue: Cost of revenue in the current fiscal year exceeded revenue, primarily due to $0.7 million of one-time costs required to upgrade our existing fleet of devices, plus $0.8 million of non-cash headwinds, either provisions for excess inventory or depreciation of devices purchased but not yet deployed.
R&D Expense Decrease: Research and development expenses for the three months ended September 30, 2024, were $4.6 million as compared to $7.1 million for the three months ended September 30, 2023. The decrease of $2.5 million was primarily attributed to a decrease in spending in salaries, stock-based compensation and preclinical studies.
Net Loss Comparison: Net loss attributed to common stockholders of Beyond Air, Inc. for the three months ended September 30, 2024, was $13.4 million or a loss of $0.28 per share basic and diluted. Our net loss attributed to common stockholders of Beyond Air, Inc. for the three months ended September 30, 2023, was $16.2 million or a loss of $0.51 per share basic and diluted.
XAIR FAQs
How does XAIR typically perform around its earnings report dates?
Is Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
XAIR Earning Call Sentiment
Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript
1.0x
00:00
00:00
XAIR.O
8.33%Positive
The earnings call presents mixed signals. Financial performance shows improvement in revenue and reduced losses, but gross margin losses and operational risks are concerns. The Q&A highlights positive contract growth but uncertainty in regulatory approvals and international sales. The private equity offering and loan extinguishment improve financial health, but lack of specific guidance on key milestones tempers enthusiasm. The market may react neutrally, balancing positive revenue trends and cost management with operational and competitive uncertainties.